<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25474" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Myoclonus</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sanders</surname>
            <given-names>Amy E.</given-names>
          </name>
          <aff>University of Connecticut School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zafar</surname>
            <given-names>Nowera</given-names>
          </name>
          <aff>Rawalpindi Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amy Sanders declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nowera Zafar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25474.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Myoclonus describes an involuntary and uncontrollable muscle contraction disorder consisting of sudden, brief, and lightning-like movements of a specific muscle, group of muscles, or even the entire body. As such, myoclonus is a clinical sign and not a diagnosis in and of itself. Myoclonus features diverse causes, anatomic diagnoses, and neurophysiologic presentations, all nonspecific concerning their neuroanatomical source and pathogenesis. Myoclonus can be a benign and temporary occurrence or a persistent and debilitating condition with a wide range of underlying etiologies, from genetic factors to neurological disorders, metabolic abnormalities, or medication side effects. Myoclonus may emerge from generalized, multifocal, focal, or segmental distributions. Understanding myoclonus is essential for healthcare professionals and individuals living with the condition, as it can significantly impact their quality of life.&#x000a0;This&#x000a0;activity&#x000a0;reviews&#x000a0;the characteristics, causes, recognition, management, and&#x000a0;collaborative strategies related to abnormal myoclonic movements,&#x000a0;empowering healthcare professionals to craft a&#x000a0;structured and organized approach to diagnosis and clinical decision-making to optimize patient care paradigms and outcomes.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the underlying pathophysiology and etiology of myoclonus to diagnose affected individuals accurately.</p></list-item><list-item><p>Develop&#x000a0;best practices for the efficient and pragmatic evaluation of myoclonus, using classification schemes based on body distribution, neurophysiology, and etiology.&#x000a0;</p></list-item><list-item><p>Select appropriate pharmacologic treatments for patients with myoclonus according to the underlying etiology.&#x000a0;</p></list-item><list-item><p>Apply interprofessional team strategies for improving care coordination and patient education to advance the treatment of myoclonus and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25474&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25474">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25474.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Myoclonus is a complex and often perplexing hyperkinetic movement disorder. Myoclonus describes an involuntary and uncontrollable muscle contraction disorder consisting of sudden, brief, and lightning-like movements of a specific muscle, group of muscles, or even the entire body. As such, myoclonus is a clinical sign and not a diagnosis in and of itself.</p>
        <p>Myoclonus features diverse causes, anatomic diagnoses, and neurophysiologic presentations, all of which are nonspecific concerning their neuroanatomical source and pathogenesis. Myoclonus can be a benign and temporary occurrence or a persistent and debilitating condition with a wide range of underlying etiologies, from genetic factors to neurological disorders, metabolic abnormalities, or medication side effects. Myoclonus may emerge from generalized, multifocal, focal, or segmental distributions.</p>
        <p>Diagnosis is facilitated by the use of a pragmatic, organized, and sequential approach to the acquisition of history and planning the necessary steps in evaluation. Treatment is according to etiology and often requires polypharmacy, which may nonetheless prove inadequate to symptomatology.&#x000a0;</p>
        <p>Understanding myoclonus is essential not only for healthcare professionals but also for individuals living with the condition, as it can significantly impact their quality of life.</p>
      </sec>
      <sec id="article-25474.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Myoclonus can be a feature of myriad neurological diseases and disorders. Perhaps most&#x000a0;pathognomonically&#x000a0;associated with "startle myoclonus" in Creutzfeld-Jakob disease, myoclonus can also be a feature of neurodegenerative diseases like Alzheimer disease, dementia with Lewy bodies, Parkinson disease, frontotemporal dementia, and disorders of basal ganglia or spinocerebellar degeneration, among others. Inflammatory conditions&#x02014;infectious, post-infectious, antibody-mediated, or paraneoplastic&#x02014;often feature myoclonic jerks. Metabolic derangement, toxidromes, physical encephalopathy, focal neurological insults, trauma, and malabsorption all can, but do not invariably, cause myoclonus. A single disease (likewise, a single individual) may manifest more than a single subtype of myoclonus.&#x000a0;</p>
        <p>The specific etiologic mechanisms underlying myoclonus remain poorly understood. At present, researchers theorize that myoclonus may emerge as a consequence of motor strip hyperexcitability, abnormalities or deficiencies in neurotransmitter receptors, imbalances between neurotransmitters, or underlying network abnormalities that have yet to be elucidated. An extensive list of possible etiologies follows, but a fully comprehensive list would be beyond the scope of this activity.</p>
        <p>Myoclonus is a clinical sign rather than a disease. The array of underlying etiologies of myoclonus is strikingly diverse. It can be bewildering unless one has a structured and organized approach to diagnosis and clinical decision-making&#x000a0;combining several (and overlapping) classification schemes. These schemes include 1) classification according to body distribution, 2) classification according to clinical presentation, and 3) classification based on results of neurophysiologic testing.<xref ref-type="bibr" rid="article-25474.r1">[1]</xref>&#x000a0; Description of new classification schemes and emendation of currently operating ones continues, especially as research unveils unknown molecular genetic causes of myoclonus.<xref ref-type="bibr" rid="article-25474.r2">[2]</xref>&#x000a0;In all cases, the structured clinical approach aims to maximize the likelihood that all possible etiologies are explored. Classification of myoclonus according to etiology based on clinical presentation is frequently the preferred starting point for the ensuing workup.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;</p>
        <p>The most basic distinction subdivides&#x000a0;myoclonus into primary and secondary phenomena, as initially proposed by Marsden et al in the early 1980s and considerably expanded upon since then. Physiologic, essential, hereditary, and epileptic myoclonus are considered primary. Secondary myoclonus, also known as symptomatic myoclonus, occurs when myoclonus results from a comorbid primary medical or neurologic condition. Virtually all pathophysiologic processes can produce myoclonus as a sign, including inflammation, infectious diseases, paraneoplastic syndromes, structural lesions, side effects of substances (licit and illicit), metabolic derangement, and degenerative disorders. Indeed, a single individual or disease state can manifest more than&#x000a0;just a single type of myoclonus.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>Primary Myoclonus</bold>
</p>
        <p>
<bold>Physiologic myoclonus</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Physiologic myoclonus is just that: physiologic. As such, it occurs as a normal phenomenon in almost everyone, albeit with considerable variability in prominence and frequency, even sometimes going entirely unnoticed by the affected individual.</p>
          </list-item>
          <list-item>
            <p>Startle responses and hiccups are examples of physiologic myoclonus that occur in most people at some point over the lifespan and, by way of treatment, usually require nothing more than explanation and reassurance.</p>
          </list-item>
          <list-item>
            <p>So, too, most myoclonic jerks occurring as part of sleep transitions (ie, hypnogogic jerks upon entering sleep) are considered physiologic. However, these jerks may disrupt restful sleep for the patient and the sleep partner, in which case treatment might be warranted.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Essential myoclonus</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Essential myoclonus is a relatively isolated occurrence in which the myoclonus is the primary, and sometimes the only, symptom. Essential myoclonus&#x000a0;tends to be either minimally or even entirely nonprogressive. By definition, other neurological systems are unaffected in essential myoclonus.<xref ref-type="bibr" rid="article-25474.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The degree of dysfunction caused by essential myoclonus varies, and for some people, the myoclonus can interfere with coordination or become moderate enough to necessitate pharmacologic intervention. That said, many affected individuals can compensate with little or no difficulty.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Essential myoclonus can occur either sporadically, in which case the etiology is usually unexplained (idiopathic), or in a hereditary fashion, usually via autosomal dominant inheritance patterns.</p>
          </list-item>
          <list-item>
            <p>Myoclonus-dystonia (also known as hereditary essential myoclonus) describes an inherited disorder wherein repetitive and rhythmic myoclonic movements occur in the upper extremities; usually, either myoclonic or dystonic movements predominate, but both must be present for the diagnosis to be valid.</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Differentiating myoclonus-dystonia from essential tremor can be tricky, particularly since both conditions tend to respond well to judicious intake of alcohol.</p>
              </list-item>
              <list-item>
                <p>Several genetic mutations have been implicated, including mutations in the&#x000a0;&#x003b5;-Sarcoglycan gene (<italic toggle="yes">SGCE</italic>)<xref ref-type="bibr" rid="article-25474.r5">[5]</xref>.</p>
              </list-item>
              <list-item>
                <p>Psychiatric symptoms often occur and may be significant; one recent long-term follow-up study noted that prevalence may increase over time.<xref ref-type="bibr" rid="article-25474.r6">[6]</xref>&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Nonmovement neurologic systems are usually, but not invariably, uninvolved.&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Epileptic myoclonus</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Epileptic myoclonus refers to seizure disorders in which the myoclonus forms all or part of the ictus.</p>
          </list-item>
          <list-item>
            <p>Myoclonus may be the sole epileptic manifestation, one of several components in seizure semiology (herein known as a "seizure fragment"), or as one type of seizure in an epilepsy syndrome with multiple and overlapping seizure subtypes.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Examples of epileptic syndromes with myoclonic seizures include:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Juvenile myoclonic epilepsy (JME): With onset usually during puberty, JME is a generalized epilepsy in which a myoclonic seizure produces the characteristic jerk. Classically described as occurring in the morning hours, myoclonic seizures occur unpredictably; the seizure threshold can be lowered by sleep deprivation, alcohol ingestion, and stress. Myoclonic seizures typically affect the upper arms, neck, and shoulders, but&#x000a0;generalized tonic-clonic seizures (affecting the entire body) also occur commonly.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Progressive myoclonic epilepsy (PME):&#x000a0;PME is a&#x000a0;progressive and sometimes fatal disorder. PME is a relatively rare epileptic syndrome that includes myoclonic seizures in combination with other neurologic dysfunction, such as ataxia, rigidity, cognitive impairment, or aphasia. More than a dozen varieties of PME have been described; the underlying molecular genetic defects have been identified for&#x000a0;Unverricht-Lundborg disease, Lafora body disease, several forms of neuronal ceroid lipofuscinoses, myoclonus epilepsy with ragged-red fibers (MERRF), and type 1 and 2 sialidoses. In most cases, the underlying genetic defect has autosomal recessive inheritance.<xref ref-type="bibr" rid="article-25474.r7">[7]</xref></p>
              </list-item>
              <list-item>
                <p>Lennox-Gastaut Syndrome (LGS): LGS describes a severe epilepsy syndrome with onset usually in infancy or early childhood. LGS is characterized by multiple and overlapping general seizure types (most commonly atonic, tonic, and atypical absence), a pathognomonic signature on electroencephalogram (EEG), cognitive dysfunction, and refractoriness to many anti-epileptic drugs.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Epilepsy with myoclonic atonic seizures (EMAS): EMAS is a rare epileptiform syndrome of early childhood, first described by Doose in 1970. EMAS is characterized by multiple types of generalized seizures, which are often followed by drop attacks that can cause falls and injuries. In some cases, persistent seizures do not respond to treatment, with resultant intellectual disability. In others, complete seizure remission&#x000a0;can occur, often after&#x000a0;several years and, in some cases, can lead to eventual normalization. Changes in the <italic toggle="yes">SCN1A, SCN1B, GABRG2, CHD2</italic>, and <italic toggle="yes">SLC6A1</italic>&#x000a0;genes&#x000a0;have been identified in EMAS, although the syndrome is frequently idiopathic.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Secondary Myoclonus&#x000a0;</bold>
</p>
        <p>Secondary myoclonus is also known as symptomatic myoclonus. Recall that symptomatic myoclonus is a clinical sign accompanying a comorbid primary neurological or other medical condition. Virtually all pathophysiologic processes can produce myoclonus as a sign, including inflammation, infectious diseases, paraneoplastic syndromes, structural lesions,&#x000a0;adverse effects of substances (licit and illicit), metabolic derangement, and degenerative disorders. Seizure(s) may be a nontrivial component of the underlying primary illness, but the seizure is not the primary myoclonus phenotype in secondary myoclonus. In secondary myoclonus, more than a single neurological system is usually affected. Sleep, cognitive, and movement impairments are commonly co-occurring.</p>
        <p>
<bold>Drug-induced</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiple drug classes and multiple different agents within each class can cause myoclonus, making it imperative that the entirety of a presenting patient's armamentarium be&#x000a0;probed for potential causation.</p>
          </list-item>
          <list-item>
            <p>Renal or hepatic dysfunction can raise the levels of myoclonus-inducing drugs and their metabolites in the bloodstream.</p>
          </list-item>
          <list-item>
            <p>Drug-induced myoclonus is frequently reversible upon withdrawal of the causative agent. However, a layer of complexity also obtains here: in some cases, discontinuation (notably of anticonvulsants&#x000a0;or sedative-hypnotics) can precipitate myoclonus.</p>
          </list-item>
          <list-item>
            <p>Polypharmacy that includes multiple potentially offending drug classes&#x000a0;(or multiple agents from a single class) can produce synergistic interactions, thus increasing the likelihood of emergent myoclonus.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bismuth</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Bismuth has been used as a wound dressing in maxillofacial and neurosurgical interventions and aftercare for burns and skin grafts. In these settings, bismuth can cause a toxic metabolic encephalopathy that includes myoclonus, along with ataxia, altered mental status, and seizures.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Acute toxicity often precipitates renal failure; subacute or chronic exposure can cause the bismuth encephalopathy syndrome. Diagnosis is via blood and urine bismuth levels, which correlate well with each other but are unable to differentiate between acute and chronic toxicity.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Bismuth toxicity can occur with both oral and topical formulations.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Bismuth toxicity can be easily missed or overlooked, necessitating a high index of suspicion.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Untreated, bismuth encephalopathy can progress to coma and death.<xref ref-type="bibr" rid="article-25474.r8">[8]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Lithium</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Lithium is frequently prescribed to individuals with mood disorders such as bipolar disorder, acute mania, or hypomania; a coarse tremor is a well-known side effect of the medication.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Lithium toxicity can cause focal motor seizures and generalized convulsions; with mild toxicity&#x02014;or even at therapeutic levels&#x02014;electroencephalographic slowing may be seen. Using sophisticated EEG techniques,<xref ref-type="bibr" rid="article-25474.r9">[9]</xref>&#x000a0;recent work has suggested that lithium-induced myoclonus is likely cortical, arising largely from the cerebellum.<xref ref-type="bibr" rid="article-25474.r10">[10]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Other drug classes and agents prominently associated with myoclonic adverse effects (noninclusive):&#x000a0;&#x000a0;
<list list-type="bullet"><list-item><p>Antibiotics: penicillins, cephalosporins, carbapenems, fluoroquinolones</p></list-item><list-item><p>Narcotics: tramadol, hydromorphone, morphine, and fentanyl</p></list-item><list-item><p>Anesthetics: lidocaine, midazolam, propofol</p></list-item><list-item><p>Anticonvulsants: gabapentin, pregabalin, lamotrigine, phenobarbital, phenytoin, valproic acid, vigabatrin, primidone, and carbamazepine</p></list-item><list-item><p>Psychiatric medications: neuroleptics, antidepressants (tricyclics and selective serotonin reuptake inhibitors)</p></list-item><list-item><p>Anti-Parkinsonian drugs (L-dopa, bromocriptine, amantadine, selegiline)</p></list-item><list-item><p>Cardiac medications: amiodarone<xref ref-type="bibr" rid="article-25474.r11">[11]</xref> and calcium channel blockers</p></list-item><list-item><p>Chemotherapeutic agents: cyclophosphamide, ifosfamide, busulphan, chlorambucil, and etomidate<xref ref-type="bibr" rid="article-25474.r12">[12]</xref>&#x000a0;&#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Metabolic conditions causing myoclonus</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic derangement, arising from organ failure or electrolyte abnormalities (or both, in unhappy scenarios), can produce myoclonus, which can be subtle, multifocal, or even persistent, as in myoclonic status epilepticus.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prognosis in metabolic myoclonus depends on the severity of the underlying derangement and on whether eventual reversibility proves possible.</p>
          </list-item>
          <list-item>
            <p>Asterixis<xref ref-type="bibr" rid="article-25474.r13">[13]</xref>&#x000a0;is a type of so-called negative myoclonus, less a jerk than a brief lapse in postural tone (usually with the arms extended and wrists dorsiflexed), giving the appearance of &#x0201c;flapping&#x0201d; due to a momentary loss of muscle tone in agonist muscles, followed immediately by a compensatory jerk of the antagonistic muscles. Once primarily associated with hepatic dysfunction (the "liver flap"), asterixis has subsequently also been noted in myriad other conditions, including Guillen-Barre syndrome,<xref ref-type="bibr" rid="article-25474.r13">[13]</xref>&#x000a0;cephalosporin toxicity,[39]&#x000a0;and hypermagnesemia,<xref ref-type="bibr" rid="article-25474.r14">[14]</xref>&#x000a0;among others.</p>
          </list-item>
          <list-item>
            <p>Common precipitants of metabolic myoclonus include:&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Renal failure</p>
              </list-item>
              <list-item>
                <p>Post-dialysis syndrome</p>
              </list-item>
              <list-item>
                <p>Hepatic failure</p>
              </list-item>
              <list-item>
                <p>Disorders of glucose metabolism (hypo- or hyper-)</p>
              </list-item>
              <list-item>
                <p>Deficiency of biotin (including in multiple carboxylase deficiency) or vitamin E</p>
              </list-item>
              <list-item>
                <p>Hyperthyroidism</p>
              </list-item>
              <list-item>
                <p>Hyponatremia</p>
              </list-item>
              <list-item>
                <p>Metabolic alkalosis</p>
              </list-item>
              <list-item>
                <p>Hypoxia</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Neurodegenerative</bold>
</p>
        <p>Myoclonus is a frequent sign in neurodegenerative diseases of many sorts, although only rarely does it aid in parsing the differential diagnosis of the underlying neurodegenerative disorder.</p>
        <list list-type="bullet">
          <list-item>
            <p>Spinocerebellar degeneration&#x000a0;
<list list-type="bullet"><list-item><p>Dyssynergia cerebellaris myoclonica (aka Ramsey Hunt syndrome). This form of progressive myoclonic ataxia is similar to PME, albeit here, the ataxia is the dominant phenotype, rather than the frequent seizures that are seen in PME.</p></list-item><list-item><p>Other forms of spinocerebellar degeneration, including myoclonus as one aspect of the phenotype, include:
<list list-type="bullet"><list-item><p>Friedreich&#x02019;s ataxia, a hereditary multisystem disorder for which a transcription factor was given FDA approval in early 2023;<xref ref-type="bibr" rid="article-25474.r15">[15]</xref></p></list-item><list-item><p>Ataxia-telangiectasia, a rare autosomal recessive disorder in which chorea or dystonia occur more commonly than myoclonus;<xref ref-type="bibr" rid="article-25474.r16">[16]</xref></p></list-item><list-item><p>Spinocerebellar ataxia describes a group of related genetic diseases (with an autosomal dominant inheritance pattern) that cause progressive impairments in cognition, motor control, and coordination, all amid considerable phenotypic heterogeneity.<xref ref-type="bibr" rid="article-25474.r17">[17]</xref>&#x000a0;</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Basal ganglia degeneration: Various degenerative disorders of the basal ganglia feature myoclonus in their phenotypes. A partial list of these disorders includes:&#x000a0;
<list list-type="bullet"><list-item><p>Wilson disease,</p></list-item><list-item><p>torsion dystonia,</p></list-item><list-item><p>neurodegeneration with brain iron accumulation (previously known as Hallervorden&#x02013;Spatz syndrome),</p></list-item><list-item><p>progressive supranuclear palsy (PSP),</p></list-item><list-item><p>Huntington disease,</p></list-item><list-item><p>Parkinson disease (PD),</p></list-item><list-item><p>multiple system atrophy (MSA),</p></list-item><list-item><p>corticobasal degeneration (CBD), and</p></list-item><list-item><p>dentatorubropallidoluysian atrophy.<xref ref-type="bibr" rid="article-25474.r1">[1]</xref></p></list-item><list-item><p>At one point in time, PSP and CBD were grouped under a rubric of &#x0201c;atypical parkinsonism&#x0201d; or &#x0201c;Parkinson-plus syndromes,&#x0201d; but&#x000a0;both are now recognized as tauopathies.<xref ref-type="bibr" rid="article-25474.r18">[18]</xref>&#x000a0; PD and MSA are synucleinopathies.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Parkinson disease (PD)&#x000a0;
<list list-type="bullet"><list-item><p>Myoclonus occurs much less commonly in idiopathic PD than the more pathognomonic and easily recognized high-amplitude, low-frequency, and usually asymmetric rest tremor. That said, rest tremors seem to occur less frequently in those PD patients who have concomitant myoclonus. In PD patients with myoclonus, the cortical burden of aberrant &#x003b1;-synuclein is markedly higher than in those who do not exhibit myoclonus.</p></list-item><list-item><p>In the mid-1970s, myoclonus in Parkinson disease was understood as an adverse effect of therapy with levodopa.<xref ref-type="bibr" rid="article-25474.r19">[19]</xref> Bromocriptine and amantadine have also been associated with myoclonus as an adverse effect, although pharmacological databases (eg, Epocrates) no longer list this effect. Myoclonus is recognized more as an &#x0201c;off&#x0201d; phenomenon in PD according to current understanding.</p></list-item><list-item><p>Orthostatic myoclonus of the lower extremities can exacerbate unsteadiness in PD.<xref ref-type="bibr" rid="article-25474.r20">[20]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Corticobasal degeneration (CBD)
<list list-type="bullet"><list-item><p>CBD refers to a broad spectrum of disorders described by fronto-basal-ganglia degeneration, leading to a progressive decline in movement, coordination, cognition, and swallowing.</p></list-item><list-item><p>Asymmetric rigidity is a hallmark of CBD, where it occurs in combination with dystonia, myoclonus, apraxia, cortical sensory deficits, or (sometimes, and certainly most famously) an alien limb phenomenon.</p></list-item><list-item><p>Both action- and stimulus-sensitive myoclonus can occur in CBD, where the myoclonus can be either asymmetric or focal. A myoclonus-predominant phenotype has been reported.<xref ref-type="bibr" rid="article-25474.r21">[21]</xref></p></list-item><list-item><p>A recent CBD autopsy case series reported that myoclonus occurred in slightly more than a quarter of the cases, which is relatively lower than previously reported prevalence rates.<xref ref-type="bibr" rid="article-25474.r22">[22]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Progressive supranuclear palsy (PSP)
<list list-type="bullet"><list-item><p>Motoric deficits in PSP can occur anywhere along the neuraxis. Several discrete phenotypes have been described,<xref ref-type="bibr" rid="article-25474.r23">[23]</xref>&#x000a0;centering on bradykinesia, rigidity, gait freezing and falls, supranuclear ocular motor impairment, dysphagia, dysarthria, incontinence, an array of behavioral changes, including frontal cognitive dysfunction, and sleep disorders.<xref ref-type="bibr" rid="article-25474.r24">[24]</xref></p></list-item><list-item><p>Myoclonus is uncommon in the classical PSP phenotype, known as Richardson&#x02019;s syndrome, in which symmetrical axial rigidity is accompanied by vertical gaze palsy, severe akinesia, and falls.</p></list-item><list-item><p>Myoclonus does occur in the combined PSP-CBS phenotype, which features prominent asymmetric dystonia, cortical sensory deficits, and the alien limb phenomena.<xref ref-type="bibr" rid="article-25474.r25">[25]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Major neurocognitive disorders (dementias)
<list list-type="bullet"><list-item><p>Major neurocognitive disorders easily number more than 50, but the &#x0201c;Big 4&#x0201d; are Alzheimer disease (AD), vascular dementia, dementia with Lewy bodies (DLB), and the frontotemporal lobar degeneration (FTLD). A recent single-institution retrospective analysis of myoclonus in neurodegenerative disease conducted at a renowned dementia research center reported a cumulative probability of developing myoclonus of 42.1%; the probability was highest in DLB (58.1%), and in all groups, the relative frequency of myoclonus increased with earlier age-at-onset.<xref ref-type="bibr" rid="article-25474.r26">[26]</xref></p></list-item><list-item><p>Most commonly, myoclonus in dementia has a cortical generator, although this is not universal. In late-onset myoclonic epilepsy in Down syndrome, for example, an EEG correlate is often missing in the later stages of the disease, indicating the presence of a subcortical, or more distal, generator.</p></list-item><list-item><p>In DLB, the myoclonic jerks usually have a large amplitude and are more likely to occur at rest than in PD, where the myoclonus can easily be confused with resting tremor. Myoclonus occurs in nearly 60% of older adults with DLB.<xref ref-type="bibr" rid="article-25474.r26">[26]</xref></p></list-item><list-item><p>In AD, myoclonus occurs in nearly half of patients, where it is usually distal, multifocal, and low in amplitude. In younger individuals, early-onset Alzheimer disease can be phenotypically similar to the progressive myoclonic epilepsies. Lamotrigine can lower the seizure threshold in patients with AD, so other medications should be used, preferably for the treatment of the myoclonus.<xref ref-type="bibr" rid="article-25474.r27">[27]</xref></p></list-item><list-item><p>Rapidly-progressive dementias, like Creutzfeld-Jakob Disease (CJD), have near-pathognomic myoclonus, insofar as myoclonus becomes essentially 100% prevalent over the disease course; at onset, the myoclonus is most commonly distal and multifocal but over time often becomes more diffuse and generalized. Nonetheless, the spectrum of movement abnormalities in CJD is unusually vast, ranging from akinesia through hypokinetic to hyperkinetic phenomenologies; in one series, myoclonus appeared in approximately 70%, second only to ataxia, which appeared in 90%.<xref ref-type="bibr" rid="article-25474.r28">[28]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Inflammatory/paraneoplastic/infectious causes of myoclonus</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory: steroid-responsive&#x000a0;encephalopathy associated with autoimmune thyroiditis
<list list-type="bullet"><list-item><p>Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT; or, more familiarly, Hashimoto encephalopathy) can present with a spectrum of neurological dysfunction. Diagnosis is via elevations in antibodies to thyroglobulin and thyroid peroxidase.<xref ref-type="bibr" rid="article-25474.r29">[29]</xref>&#x000a0;</p></list-item><list-item><p>Myoclonus is often part of the clinical presentation, along with tremor, ataxia, seizures, and psychosis. One recent systematic review noted that the myoclonus is usually stimulus-sensitive and lacks EEG correlation; it was present in 42% to 65% of reported cases.<xref ref-type="bibr" rid="article-25474.r30">[30]</xref></p></list-item><list-item><p>&#x0201c;Pretreatment&#x0201d; criteria include (1) subacute onset of cognitive impairment, psychiatric symptoms, or seizures; (2) euthyroid status or mild hypothyroidism; (3) serum thyroid peroxidase antibodies (TPOAb) &#x0003e;200 IU/mL; (4) absent neuronal antibodies in serum/CSF; and (5) no other etiologies. However, a recent analysis determined that the pretreatment criteria are poor predictors of eventual steroid responsiveness, with the result that the authors recommended systematic exclusion of antibody-mediated encephalitis before steroid initiation.<xref ref-type="bibr" rid="article-25474.r31">[31]</xref>.&#x000a0;</p></list-item><list-item><p>Other presentations are also possible, including pure cerebellar ataxia; case reports in the medical literature have also described presentations entirely without encephalopathy.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Inflammatory: Other Autoimmune Encephalitides (AIE)
<list list-type="bullet"><list-item><p>Some epidemiological studies suggest that AIE may occur as commonly as infectious encephalitis, with an AIE estimated prevalence rate of 13.7/100 000.<xref ref-type="bibr" rid="article-25474.r32">[32]</xref>&#x000a0;Other studies contend that AIE is a rare disorder with a cumulative incidence of&#x02009;approximately&#x02009;3 to 9 per million person-years.<xref ref-type="bibr" rid="article-25474.r33">[33]</xref></p></list-item><list-item><p>In recent years, an ever-growing number of antibodies targeting either neuronal surface or synaptic antigens has been identified and characterized, including N-Methyl D-Aspartate Receptor (NMDAR)-antibody and Leucine-rich glioma inactivated (LGI1)-antibody.<xref ref-type="bibr" rid="article-25474.r32">[32]</xref></p></list-item><list-item><p>Atypical presentations of neurodegenerative decline should always prompt consideration of possible underlying autoimmune etiologies. Relevant symptoms favoring AIE over more typical neurodegenerative diseases might include 1) subacute rather than gradual deterioration; 2) a waxing and waning pattern; 3) any history of autoimmune disease; 4) concurrent epileptic seizures; and 4) presence of myoclonus.</p></list-item><list-item><p>In AIE, movement disorders, including myoclonus, have been associated with multiple antibodies, including anti-NMDAR, CASPR2, LGI1, Ri, Hu, or CV2/CRMP5.<xref ref-type="bibr" rid="article-25474.r34">[34]</xref><xref ref-type="bibr" rid="article-25474.r35">[35]</xref><xref ref-type="bibr" rid="article-25474.r34">[34]</xref></p></list-item><list-item><p>Autoimmune encephalitis (AIE) may present with prominent cognitive disturbances without overt inflammatory changes in MRI and CSF. Identifying these dementia mimickers is crucial because patients with AIE generally respond to immunotherapy.<xref ref-type="bibr" rid="article-25474.r36">[36]</xref> However, when an AIE is misdiagnosed, the resulting anti-inflammatory treatment also has associated morbidity - systemic steroids can cause infection, psychosis, avascular necrosis of the hip, and heart failure; intravenous immunoglobulin can cause aseptic meningitis, confusion, and hair loss; other immunosuppressive medications (eg, rituximab, azathioprine, and others) often cause headache and nausea.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Paraneoplastic Syndromes (PNS)
<list list-type="bullet"><list-item><p>Paraneoplastic disorders arise when a misguided immune-mediated pathogenetic process occurs remotely to the underlying primary malignancy.<xref ref-type="bibr" rid="article-25474.r37">[37]</xref></p></list-item><list-item><p>In adults, paraneoplastic phenomena are associated with an array of underlying cancers, including lung, breast, ovarian, and renal tumors.</p></list-item><list-item><p>Though recent population-based studies of the incidence of PNS are few, PNS appears to be a rare disorder, with incidence varying between 1.6 to 8.9 per million person-years. A reasonable interpretation of this data suggests that underdiagnosis or misdiagnosis is occurring, likely along with underreporting.<xref ref-type="bibr" rid="article-25474.r38">[38]</xref></p></list-item><list-item><p>Stiff Person Syndrome (SPS) describes an array of conditions characterized by fluctuating muscle stiffness, superimposed spasms, and exaggerated startle.<xref ref-type="bibr" rid="article-25474.r39">[39]</xref></p></list-item><list-item><p>Progressive encephalomyelitis with rigidity and myoclonus (PERM) is one (of several) SPS subtypes. In PERM, rigidity and myoclonus occur in approximately 80% of diagnosed cases, often with an attendant increase in falls, which can be disabling. Numerous antibodies have been associated with PERM, including glycine receptor antibodies, which can be nonneoplastic.<xref ref-type="bibr" rid="article-25474.r40">[40]</xref>&#x000a0;<xref ref-type="bibr" rid="article-25474.r37">[37]</xref></p></list-item><list-item><p>Opsoclonus-myoclonus Syndrome (OMS)<xref ref-type="bibr" rid="article-25474.r41">[41]</xref>&#x000a0;<xref ref-type="bibr" rid="article-25474.r42">[42]</xref>
<list list-type="bullet"><list-item><p>OMS is colloquially known as &#x0201c;dancing eyes, dancing feet syndrome,&#x0201d; and in humans, it has been associated with a spectrum of malignancies, including breast, lung, ovarian, and testicular cancers.</p></list-item><list-item><p>Opsoclonus, from Greek for eye (&#x0201c;ops&#x0201d;) and violent, confusing movements (&#x0201c;klonus&#x0201d;), is defined as rapid, irregular, and nonrhythmic eye movements that are nonetheless conjugate. Linear and rotational movements occur in combination and are rapid, with frequencies up to 10 movements per second.</p></list-item><list-item><p>OMS in adults can also emerge due to infectious (eg, Covid),<xref ref-type="bibr" rid="article-25474.r43">[43]</xref><xref ref-type="bibr" rid="article-25474.r44">[44]</xref> tick-borne illnesses<xref ref-type="bibr" rid="article-25474.r45">[45]</xref>), autoimmune, or drug-induced etiologies.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref></p></list-item><list-item><p>In comparison with idiopathic OMS, paraneoplastic OMS has a more refractory course.<xref ref-type="bibr" rid="article-25474.r39">[39]</xref></p></list-item><list-item><p>Many antibodies have been associated with OMS, prominently including ANNA2 (anti-Ri), ANNA1 (anti-Hu), Ma2, CRMP5 (anti-CV2), NMDA-R, and GluD2.<xref ref-type="bibr" rid="article-25474.r39">[39]</xref></p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Infections: The list is multitudinous and noninclusive.
<list list-type="bullet"><list-item><p>Subacute sclerosing panencephalitis (post-viral; measles)</p></list-item><list-item><p>Arbovirus encephalitis</p></list-item><list-item><p>Herpes simplex encephalitis</p></list-item><list-item><p>Human T-lymphotropic virus</p></list-item><list-item><p>Human immunodeficiency virus</p></list-item><list-item><p>Coronavirus infection<xref ref-type="bibr" rid="article-25474.r44">[44]</xref><xref ref-type="bibr" rid="article-25474.r46">[46]</xref></p></list-item><list-item><p>Progressive multifocal leukoencephalopathy (JC virus)</p></list-item><list-item><p>Bacterial infection including these causative organisms:&#x000a0;<italic toggle="yes">Streptococcus,&#x000a0;Clostridium, Treponema pallidum</italic> (syphilis), <italic toggle="yes">Cryptococcus, Borrellia burgdorferei</italic> (Lyme disease), and&#x000a0;<italic toggle="yes">Tropheryma whipplei&#x000a0;</italic>(Whipple disease)&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Posthypoxic Myoclonus</bold>
</p>
        <p>The clinical spectrum of post-hypoxic movement disorders incorporates post-hypoxic dystonia, ballism, choreoathetosis, akinetic-rigid syndrome, and myoclonus among its diverse manifestations.<xref ref-type="bibr" rid="article-25474.r47">[47]</xref></p>
        <p>More specifically, causes of post-hypoxic myoclonus include cardiac arrest, respiratory obstruction, anesthesia accident, carbon monoxide poisoning, hemorrhagic shock, hanging, and drowning.<xref ref-type="bibr" rid="article-25474.r48">[48]</xref></p>
        <p>Posthypoxic myoclonus (PHM) presents with focal or generalized, stimulus-sensitive myoclonic jerks beginning days to weeks after cardiac arrest, sometimes without reliable correlates on electroencephalography (EEG).[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/10.1111/ene.14326#ene14326-bib-0005">5</ext-link>]</p>
        <p>According to the timing of emergent myoclonus, PHM can be acute or chronic.<xref ref-type="bibr" rid="article-25474.r49">[49]</xref>&#x000a0;Acute PHM usually emerges within the first 48 hours after an ischemic hypoxic brain injury; it can be multifocal or generalized, and it often appears while the patient is still comatose. Many cases have a subcortical generator, but cortical myoclonus also occurs; the latter increases the risk for the development of myoclonic status epilepticus. EEG findings in acute PHM range from burst suppression, spike-wave activity, diffuse slow background, and generalized periodic discharges, to alpha coma. Prognosis in acute PHM is likewise variable, ranging from complete recovery to death.</p>
        <p>Chronic PHM, also known as Lance-Adams syndrome (LAS), has a generally more favorable prognosis, owing at least in part to the usual absence of an underlying ischemic brain injury. LAS usually emerges on a subacute or chronic time scale, but emergence as early as the first 96 hours has been reported, which can lead to diagnostic uncertainty between PHM and LAS. EEG findings in LAS may feature spike-wave, poly-spike activity, or slow frequency waves; up to 50% of EEGs in LAS demonstrate focal epileptiform activity at the vertex, considered by some to be a defining feature of LAS.<xref ref-type="bibr" rid="article-25474.r49">[49]</xref></p>
        <p>Because it is effective for both cortical and subcortical origins of myoclonus, clonazepam is, in many cases, the first-line therapy for both PHM and LAS. Other agents, generally either antiseizure medications or anesthetic agents, are also often used; treatment with more than one medication is frequently necessary, and refractoriness may nonetheless remain.</p>
        <p>
<bold>Functional Jerks</bold>
</p>
        <p>A psychogenic etiology can give rise to phenomena difficult to distinguish from the "organic" etiologies of myoclonus. Hints that a so-called functional etiology is at play include acute onset, sudden spontaneous resolution, amelioration with distraction, and inconsistencies in amplitude, frequency, and distribution of the jerks.<xref ref-type="bibr" rid="article-25474.r50">[50]</xref>&#x000a0;In some cases, identification of a Bereitschaft potential ("preparing" potential) or event-related desynchronization on EEG, indicators of premotor activity in advance of a voluntary movement, can support the diagnosis of functional jerks. However, these phenomena can be technically challenging to observe, so their absence should not be used to eliminate the possibility of a functional etiology.<xref ref-type="bibr" rid="article-25474.r51">[51]</xref></p>
      </sec>
      <sec id="article-25474.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Regrettably, our most current knowledge of the epidemiology of myoclonus is grievously outdated. As of 1990, the lifetime prevalence of myoclonus was 8.6% in the overall population.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;It is generally accepted that myoclonus is an important contributor to many syndromes and diseases, but its incidence and prevalence are almost certainly underestimated because myoclonus is most often secondary to another cause or underlying disorder. In some diseases that feature myoclonus as a phenotypic component, prevalence and incidence estimates vary quite widely,<xref ref-type="bibr" rid="article-25474.r52">[52]</xref><xref ref-type="bibr" rid="article-25474.r53">[53]</xref>&#x000a0;underscoring the&#x000a0;crucial lack of disorder-specific epidemiology: it is worthy of further study.<xref ref-type="bibr" rid="article-25474.r54">[54]</xref>&#x000a0;It should be recognized&#x000a0;that a single disease or patient may have more than&#x000a0;a single myoclonus neurophysiology type.&#x000a0;One study found that electrophysiological testing in the context of clinical findings altered the myoclonus diagnosis and the subtype in 53% of patients.<xref ref-type="bibr" rid="article-25474.r55">[55]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25474.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Myoclonus can arise anywhere along the neuraxis, from the cerebral cortex to the peripheral nerves.&#x000a0;Researchers theorize that myoclonus may emerge due to motor strip hyperexcitability, abnormalities or deficiencies in neurotransmitter receptors, imbalances&#x000a0;among neurotransmitters, or underlying network abnormalities that have yet to be elucidated.&#x000a0;</p>
        <p>One of the chief classification schemes for the evaluation of myoclonus rests upon identifying the neuroanatomic generator of the myoclonus. Myoclonus can arise from loci in the cortex, cortico-subcortical regions (eg, brain stem), subcortical non-segmental overlap, segmental (brain stem or spinal cord), and the peripheral nerves.</p>
        <p>
<bold>Cortical Myoclonus&#x000a0;</bold>
</p>
        <p>Cortical myoclonus may occur spontaneously, in response to somatic stimuli, or during movement.&#x000a0;Cortical myoclonus describes those muscle jerks that can be traced back to hyperexcitability in the cerebral cortex, usually in the motor strip in the precentral gyrus, conceptually described by the motor homunculus.<xref ref-type="bibr" rid="article-25474.r56">[56]</xref>&#x000a0;Cortical myoclonus predominantly affects body regions with the most extensive cortical homuncular representations, such as the hands and face. Current understanding&#x000a0;posits that cortical myoclonus&#x000a0;results from spreading cortical hyperexcitability: excitation begins in one spot on the homunculus, then spreads with a multifocal distribution, and culminates in jerking movements of the limbs with synchronous (sometimes bilateral) activation of adjacent muscles.&#x000a0;</p>
        <p>EMG discharges in cortical myoclonus are usually less than 100 ms long; spread to adjacent and antagonistic muscles can be observed.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;Examples of cortical myoclonus include chronic post-hypoxic myoclonus (LAS), the progressive myoclonic epilepsies, neurodegeneration of the Alzheimer or Lewy body type, and some drug-induced (eg, lithium) reactions.&#x000a0;&#x000a0;</p>
        <p>
<bold>Cortical-Subcortical Myoclonus</bold>
</p>
        <p>Cortical-subcortical myoclonus usually occurs in the setting of primary generalized epilepsy. Abnormal and excessive neuronal activity spreads between cortical and subcortical networks, creating diffuse electrical excitation distinct from localized cortical myoclonus, and necessitating a wholly separate neurophysiological classification. Typically, generalized myoclonus occurs due to the widespread and simultaneous spread of excitation over the sensorimotor cortex.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;</p>
        <p>EMG discharges in cortical-subcortical myoclonus are characteristically brief, averaging between 50 to 100 ms. The discharges visible on surface EMG can be correlated temporally to a spike- or polyspike&#x000a0;EEG waveform.</p>
        <p>Examples include the myoclonic seizures in JME and myoclonus associated with absence seizures.</p>
        <p>
<bold>Subcortical-Nonsegmental Myoclonus</bold>
</p>
        <p>Physiological mechanisms and results of electrophysiological testing are more heterogeneous in subcortical-nonsegmental myoclonus than in either cortical or cortical-subcortical myoclonus. Myoclonus can be generated at any of multiple subcortical locations, when&#x000a0;the excitation is&#x000a0;transmitted to descending motor pathways.&#x000a0;</p>
        <p>EMG discharges in subcortical-nonsegmental myoclonus tend to be longer in duration than in cortical or cortical-subcortical myoclonus, often as long as 200 ms. Muscle activation patterns are also variable, including bidirectional rostral-caudal distribution, a purely caudal distribution, or multifocal distribution. As a general rule, the EEG in subcortical-nonsegmental myoclonus does not show a correlation to the muscle jerks; indeed, in most cases, the EEG is normal. However, given that multiple physiological and technical factors may influence electrophysiological recordings, subcortical-nonsegmental should never be diagnosed solely on the absence of findings typical of cortical myoclonus.<xref ref-type="bibr" rid="article-25474.r1">[1]</xref></p>
        <p>In brainstem reticular myoclonus, an initial discharge arises in muscles (trapezius and sternocleidomastoid) innervated by the spinal accessory nerve (CN XI); this is followed by the rostral spread of the excitation, which causes jerks first in the muscles of facial expression (CN VII) and then masseter jerks (CN V). In propriospinal myoclonus, the generator&#x000a0;arises in the cervical or thoracic spinal cord and is again followed by muscle recruitment in both rostral and caudal directions; this kind of myoclonus sometimes arises from spinal lesions, but it can also be seen in sleep transitions (physiological myoclonus).&#x000a0;In myoclonus dystonia, the discharge pattern is multifocal; the cause is thought to be genetic mechanisms affecting the basal ganglia and cerebellothalamic circuits. This myoclonus syndrome reportedly is exquisitely responsive to ethanol.</p>
        <p>
<bold>Segmental Myoclonus</bold>
</p>
        <p>Segmental myoclonus refers to myoclonus arising in and limited to 1-3 contiguous segments of the brainstem or spinal cord. Discharges are often persistent and are not usually impacted by the level of consciousness, motor activity, stimuli, or other exogenous factors.&#x000a0;</p>
        <p>EMG discharges in segmental myoclonus are distinctive by their duration, which&#x000a0;can be as long as 500 ms, and their highly rhythmic nature.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;As with subcortical-nonsegmental myoclonus, no EEG correlate of muscle activity is usually observed in segmental myoclonus.&#x000a0;</p>
        <p>The classic example of segmental myoclonus is palatal myoclonus, which can occur idiopathically or due to dentato-rubro-olivary&#x000a0;(the Guillain Mollaret triangle) lesions. Occasionally, the palatal myoclonus may be functional.&#x000a0;</p>
        <p>Spinal segmental myoclonus can arise from vascular, neoplastic, inflammatory, infectious, and idiopathic causes. Anterior horn cell hyperexcitability in the affected segment is felt to be the cause due to loss of spinal neuron inhibition.&#x000a0;Segmental&#x000a0;myoclonus is often refractory to pharmacological intervention.&#x000a0;</p>
        <p>
<bold>Peripheral Myoclonus</bold>
</p>
        <p>Peripheral myoclonus arises from one or more elements of the peripheral nerve itself (eg, root or nerve). Multiple muscles within a single nerve distribution may be affected. Direct motor nerve irritation (usually due to compression) or peripheral nerve lesions altering central nervous system motor pathways have been advanced as proposed mechanisms.&#x000a0;</p>
        <p>Hemifacial spasm, wherein the generator lies in the muscles of facial expression innervated by the facial nerve (CN VII), is the best-known example of peripheral myoclonus.&#x000a0;</p>
      </sec>
      <sec id="article-25474.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Myoclonus can be an overwhelming and intimidating presentation for the practitioner who does not have an efficient and practical approach to carrying out the clinical evaluation.</p>
        <p>
<bold>History</bold>
</p>
        <p>A comprehensive history is the critical foundational starting point in evaluating myoclonus, with a particular focus on aspects of the history that could be relevant to the emergence of myoclonus. Both the history and the physical examination can provide salient clues to aid in distinguishing symptomatic from the other subtypes of myoclonus.</p>
        <p>Key elements of the history&#x000a0;crucial to review in every patient with myoclonus include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age at onset: childhood, early adulthood, or late adulthood.</p>
          </list-item>
          <list-item>
            <p>Phenomenology of the myoclonus: Triggers&#x000a0;(eg, auditory stimulus, movement, and tactile, visual, or emotional stimuli), body parts involved, and whether the myoclonus displays rhythmicity.<xref ref-type="bibr" rid="article-25474.r57">[57]</xref></p>
          </list-item>
          <list-item>
            <p>Family history: A&#x000a0;positive family history hints at the possibility of a genetic contribution to the myoclonus, including possibly from the myoclonic epilepsies.</p>
          </list-item>
          <list-item>
            <p>Chronicity
<list list-type="bullet"><list-item><p>acute, suggesting perhaps a toxic effect of medication;</p></list-item><list-item><p>subacute, suggesting possible infectious (or postinfectious), inflammatory, paraneoplastic, or toxic-metabolic causation;</p></list-item><list-item><p>or chronic, which is usually indicative of genetic or neurodegenerative causes. Of note, the chronic onset of focal myoclonus may herald underlying neoplasm.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Progression: rapidly progressive, slowly progressive, static.</p>
          </list-item>
          <list-item>
            <p>Coinciding factors
<list list-type="bullet"><list-item><p>new medication(s), newly-discontinued medications, or dosage changes in continuing medications,</p></list-item><list-item><p>sick exposures,</p></list-item><list-item><p>the presence of concomitant symptoms, especially if they are neurologic (eg, cognitive decline, paresthesias, weakness, &#x0201c;spells&#x0201d; of altered awareness, or loss of consciousness), or</p></list-item><list-item><p>whether consumption of alcohol ameliorates the myoclonic jerks (think myoclonus-dystonia).</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Physical and Neurological Examination</bold>
</p>
        <p>The examination facilitates the acquisition of important information about 1) the body distribution of the myoclonus, 2) its constancy, and 3) whether the myoclonus can be induced by stimulus (eg, auditory, tactile, startle). Every examination&#x000a0;should assess&#x000a0;for movement characterization of the myoclonus and include a thorough neurological examination.&#x000a0;</p>
        <p>The clinician must evaluate the distribution of the movements,&#x000a0;including&#x000a0;amplitude, and observe for any activation characteristics. Neuroanatomical correlation is not perfect, but can guide the clinician's initial thinking along the following lines:</p>
        <list list-type="bullet">
          <list-item>
            <p>Myoclonus in the resting state suggests a spinal or brainstem source, but action-induced myoclonus points to a cortical origin.</p>
          </list-item>
          <list-item>
            <p>Focal and multifocal jerks, prompted by voluntary action, typify cortical myoclonus.</p>
          </list-item>
          <list-item>
            <p>Spinal segmental myoclonus is usually also focal, although contrary to cortical myoclonus, it is not action-induced and is occasionally stimulus-sensitive.</p>
          </list-item>
          <list-item>
            <p>Generalized myoclonus is usually subcortical (brainstem or propriospinal myoclonus); a cortical generator will occasionally be revealed for generalized myoclonus.&#x000a0;</p>
          </list-item>
        </list>
        <p>To elicit eloquent neurologic signs, a comprehensive neurological examination is paramount in the evaluation of myoclonus:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cognitive dysfunction may indicate underlying dementia (or dementia prodrome).</p>
          </list-item>
          <list-item>
            <p>Signs of parkinsonism may point to an underlying tau- or synucleinopathy.</p>
          </list-item>
          <list-item>
            <p>Dystonia may corroborate suspicions of myoclonus-dystonia.</p>
          </list-item>
          <list-item>
            <p>Cerebellar signs may point to a cerebellar ataxia syndrome.<xref ref-type="bibr" rid="article-25474.r58">[58]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Eye movements should be assessed to rule out (or in) opsoclonus-myoclonus.</p>
          </list-item>
          <list-item>
            <p>Finally, a careful examination should be conducted to assess for signs of systemic disease. &#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25474.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>As with the history and physical examination, it is&#x000a0;vital to have a systematic approach to ancillary testing in the workup of myoclonus. Ancillary testing builds on the history and physical examination to identify the underlying etiology. The first goal is always to determine whether a reversible cause for the myoclonus exists. The fundamental building blocks of a systematic approach include basic laboratory testing, ancillary laboratory testing when warranted, and more comprehensive testing if needed and based on the results of the initial stages of testing. Following Occam's Razor,<xref ref-type="bibr" rid="article-25474.r59">[59]</xref> should&#x000a0;the myoclonus present along with non-myoclonus signs and symptoms, the clinician must seek a unifying single diagnosis.</p>
        <p>
<bold>Basic Laboratory Testing</bold>
</p>
        <p>Tests for serum electrolytes, glucose, renal and hepatic function tests, and at least basic thyroid studies (ie, thyroid stimulating hormone and circulating free T4 thyroid hormone) should be obtained in nearly every patient who presents with myoclonus. No laboratory work is necessary in clear-cut cases of&#x000a0;physiologic myoclonus, where there are no signs or aspects of the history raising concerns for other etiologies.&#x000a0;</p>
        <p>Drug and toxin screening is essential to consider in the case of acute onset myoclonus or the hospital (inpatient or emergency department) setting.&#x000a0;</p>
        <p>A lumbar puncture is essential whenever possible infectious or inflammatory causation is suspected. Standard studies for cell counts, glucose, and protein should always be obtained; antibody and paraneoplastic panels should be sent&#x000a0;in the setting of possible inflammatory or paraneoplastic causes of myoclonus. Concern for possible CJD necessitates sending CSF for RT-QUIC testing<xref ref-type="bibr" rid="article-25474.r60">[60]</xref> to the National Prion Disease Pathology Surveillance Center in Cleveland, OH.&#x000a0;</p>
        <p>
<bold>Neurophysiological Testing and Structural Neuroimaging Neurophysiological Testing</bold>
</p>
        <p>Electroencephalography (EEG) must be performed in all but the most straightforward presentations of physiological myoclonus. EEG alone can advance the diagnostic reasoning in cases of myoclonic epilepsies. However, the most broadly informative approach combines EEG with electromyography (EMG) on muscles of interest. The technique of EEG-EMG back-averaging (correlation of electrical activity on EEG in the brain with muscle jerking on EMG) shows cortical discharge preceding the activity on electromyography. Even when the EEG has no clinical correlate, the absence of myoclonic cortical activity can be instructive, as in cases of subcortical-nonsegmental myoclonus (eg, propriospinal, brainstem reticular myoclonus, or myoclonus-dystonia). Evoked potentials can be helpful in some segmental or peripheral myoclonus cases, but they are not pathognomic.&#x000a0;</p>
        <p>
<bold>Structural Neuroimaging</bold>
</p>
        <p>Brain MRI should be considered and is particularly important in cases of symptomatic myoclonus. Brain MRI can aid in discovering ischemic insult, mass lesion, or infectious nidus. The study should be ordered with gadolinium if inflammation, infection, or mass lesion figure prominently in the differential diagnosis. Brain MRI can also be helpful in segmental myoclonus cases; segmental or peripheral myoclonus necessitate imaging of the spinal cord and even peripheral nerves in some cases.&#x000a0;</p>
        <p>
<bold>More Comprehensive Testing</bold>
</p>
        <p>If the etiology of the myoclonus remains unclear after the initial rounds of testing, more comprehensive testing will be needed. The issue is that the corpus of eligible tests is enormous, underscoring the demand for a targeted strategy with a stepwise evolution.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;Possible avenues to pursue include genetic testing, which could be either for specific genetic markers or for possibly whole exome sequencing,<xref ref-type="bibr" rid="article-25474.r58">[58]</xref> inflammatory and paraneoplastic antibodies (if not previously obtained), or specific toxins not previously evaluated. A lumbar puncture may be helpful if not performed during earlier testing.&#x000a0;</p>
      </sec>
      <sec id="article-25474.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Myoclonus is notoriously refractory to pharmacotherapy. Additional complexity arises due to the relatively undeveloped evidence base and near total absence of formal, consensus- and evidence-based guidelines.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref> For these reasons, it is a near-maxim that the etiology of the myoclonus, as it emerges from a proper history and neurophysiological assessment, must drive the treatment choice.<xref ref-type="bibr" rid="article-25474.r1">[1]</xref> In many cases, polypharmacy will become necessary to control the myoclonus. Cumulatively, these factors preclude the creation of precise treatment algorithms and greatly complicate the approach to treatment in myoclonus.</p>
        <p>Should the myoclonus etiology remain opaque, empirical treatment&#x000a0;should be explored. In all cases, the selected treatment must be measured against its possible&#x000a0;adverse effects. This is particularly the case given that some treatments have the potential to worsen cognitive function, cause neuropsychiatric comorbidities, or impair movement coordination.&#x000a0;</p>
        <p>In most cases, standard titration schedules for a given medication are adequate when used to treat myoclonus. However, for patients already burdened by polypharmacy in the setting of multiple and complex medical problems, slower titration schedules should always be considered. Metabolic insufficiency&#x02014;especially renal or hepatic compromise&#x02014;should prompt the use of lower doses and slower titration schedules.&#x000a0;</p>
        <p>In some cases of myoclonus, disability occurs even after optimal symptomatic treatment has occurred. Physical and occupational therapy warrant examination for inclusion in the overall treatment paradigm, especially for symptomatic myoclonus.</p>
        <p>In physiological myoclonus, pharmacotherapy is usually not necessary. In cases of suspected drug-induced myoclonus, a trial off of the offending causal agent (or dose reduction, in some cases) along with correction of any associated metabolic derangement is the necessary first step.&#x000a0;</p>
        <p>
<bold>Treatment of Cortical Myoclonus</bold>
</p>
        <p>Cortical hyperexcitability is an intrinsic cause of cortical myoclonus, and, consistent with this, anti-epileptic drugs (AEDs) are the usual first-line treatment approach. That said, AEDs can, in some cases, worsen the myoclonus.<xref ref-type="bibr" rid="article-25474.r61">[61]</xref>&#x000a0;Valproic acid, levetiracetam, clonazepam, and perampanel are commonly used, with at minimum some case reports as the underlying evidence base (although not all agree fully) for each agent. Topiramate and zonisamide are used on occasion in the setting of&#x000a0;</p>
        <p>
<bold>Levetiracetam</bold>
</p>
        <p>A relatively "clean" AED, with renal rather than hepatic clearance and a comparatively mild side effect profile, levetiracetam<xref ref-type="bibr" rid="article-25474.r62">[62]</xref> is frequently the first-line therapy in cortical myoclonus. Its antimyoclonic effect is theorized to arise from its binding to the synaptic vesicle protein 2A (SV2A), although the precise mechanism of action has not yet been established. Standard dosing regimens fall between 1000 and 3000 mg daily, divided into two doses. Side effects include headache, dizziness, and fatigue. Behavioral side effects sometimes limit its usage, but these are more common in the treatment of epilepsy(3-4%) than myoclonus.<xref ref-type="bibr" rid="article-25474.r62">[62]</xref></p>
        <p>
<bold>Valproic acid&#x000a0;</bold>
</p>
        <p>An older AED valproic acid (VPA) can be beneficial in cortical myoclonus, albeit considered a second-line approach by some well-known authorities<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;and a first-line treatment for myoclonic epilepsies by others.<xref ref-type="bibr" rid="article-25474.r1">[1]</xref> VPA likely acts through multiple mechanisms that increase the availability of gamma-aminobutyric acid (GABA) through amplified synthesis and decreased degradation.<xref ref-type="bibr" rid="article-25474.r62">[62]</xref>&#x000a0;Standard dosing regimens range between 500 and 2000 mg daily, with higher doses often needed to achieve symptomatic control. VPA is regarded as a relatively "messy" AED, given its manifold adverse effects. These include hepatotoxicity, metabolic derangement (SIADH, hyponatremia), blood dyscrasias (pancytopenia, thrombocytopenia, myelosuppression, aplastic anemia, and others), encephalopathy, psychosis, and suicidality number only some of the serious adverse events associated with VPA. Common side effects include headache, gastrointestinal distress, weight gain, tremor, sleep issues (both somnolence and insomnia can occur), and alopecia. VPA is contraindicated in pregnancy (and in women who wish to become pregnant).&#x000a0;</p>
        <p>
<bold>Clonazepam</bold>
</p>
        <p>A benzodiazepine, clonazepam, likely facilitates GABAergic transmission. A scant array of (now outdated) case reports&#x000a0;suggest a possible role in posthypoxic and neurodegenerative etiologies of myoclonus. Benefits have also been described for clonazepam in the settings of opsoclonus-myoclonus, spinal myoclonus, and especially in cases of chronic posthypoxic myoclonus.&#x000a0;</p>
        <p>
<bold>Perampanel</bold>
</p>
        <p>A relative newcomer among AEDs, perampanel gained FDA approval in 2012. Though its exact mechanism is unknown, it is believed to antagonize&#x000a0;&#x003b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), thus reducing glutamate-mediated neuronal excitation. As with other AEDs used in myoclonus, the evidence base for perampanel in myoclonus is thin, consisting primarily of small (eg, n of 2)<xref ref-type="bibr" rid="article-25474.r63">[63]</xref> cases series suggesting its utility in cortical myoclonus arising in the myoclonic epilepsies<xref ref-type="bibr" rid="article-25474.r64">[64]</xref> and in posthypoxic myoclonus.<xref ref-type="bibr" rid="article-25474.r65">[65]</xref><xref ref-type="bibr" rid="article-25474.r66">[66]</xref>&#x000a0;Behavioral adverse effects include a range of dysfunction: worsening depression, hostility, aggression, suicidal and homicidal ideation, and abuse. Common side effects include gastrointestinal discomfort, vertigo, headache, fatigue, and weight gain, among many others.<xref ref-type="bibr" rid="article-25474.r65">[65]</xref></p>
        <p>
<bold>Treatment of Cortical-Subcortical Myoclonus</bold>
</p>
        <p>Though there is some overlap with the treatment of cortical myoclonus, some authorities believe cortical-subcortical myoclonus demonstrates a "distinct profile of therapeutic efficacy."<xref ref-type="bibr" rid="article-25474.r1">[1]</xref> VPA remains the usual first-line approach to the syndromes of generalized epilepsy featuring myoclonus (primarily JME and absence syndromes). Currently, clinical equipoise characterizes the use of lamotrigine in JME, particularly in comparison to VPA; rarely does lamotrigine reportedly worsen myoclonus in JME.&#x000a0;</p>
        <p>
<bold>Treatment of Subcortical-Nonegmental Myoclonus</bold>
</p>
        <p>Given the etiologic heterogeneity that attends this myoclonus category, so is there heterogeneity in treatment approaches. Clonazepam is reasonable to try first in cases ranging from reticular reflex myoclonus to myoclonus-dystonia (which often responds exquisitely to alcohol, too) to propriospinal myoclonus. Zonisamide, an inhibitor of carbonic anhydrase that blocks sodium and calcium channels, demonstrated benefit in myoclonus-dystonia in a recent(ish) double-blind crossover trial in a small cohort (n = 23) of patients.<xref ref-type="bibr" rid="article-25474.r67">[67]</xref></p>
        <p>Levetiracetam and VPA typically have limited utility in subcortical-nonsegmental myoclonus. (goes under&#x000a0;Treatment of Subcortical-Nonegmental Myoclonus</p>
        <p>
<bold>Treatment of Segmental Myoclonus</bold>
</p>
        <p>Segmental myoclonus is infamously unresponsive to pharmacotherapy. Clonazepam and baclofen are often tried empirically. OnabotulinumtoxinA (Botox) injections have shown promise in a small set of now outdated publications<xref ref-type="bibr" rid="article-25474.r1">[1]</xref> concerning palatal myoclonus and spinal myoclonus; close monitoring for serious adverse events is essential with Botox, as these can include dysphagia, respiratory compromise, and dysautonomia.&#x000a0;</p>
        <p>
<bold>Treatment of Peripheral Myoclonus</bold>
</p>
        <p>At one time, carbamazepine, usually used to treat complex partial seizures, was the mainstay of treatment in the most common example of peripheral myoclonus, hemifacial spasm. Today, Botox is the preferred approach, with surgical intervention as a consideration in cases where a compressive lesion is found.</p>
        <p>
<bold>Treatment of Functional Jerks</bold>
</p>
        <p>It is crucial to achieve the maximal possible certainty of the functional diagnosis before attempting to treat psychogenic movement disorders of any sort, and this includes functional jerks. The first step in treatment must always be to explain the functional nature of the symptoms in an empathic manner that eschews any suggestion that the problem is "all in the head." Treatment usually requires a multidisciplinary approach, individualized to the patient. Pharmacotherapy of the functional jerks is not indicated in the vast majority of cases, but comorbid psychiatric conditions should, in all cases, be addressed with medications in the presence of positive indications. Other modalities that may help in functional jerks include cognitive behavioral therapy, physical therapy, physical activity, and biofeedback.&#x000a0;</p>
        <p>
<bold>Treatment Trends</bold>
</p>
        <p>Deep brain stimulation (DBS) involves the implantation of an electrical stimulator&#x000a0;&#x02014; akin to a cardiac pacemaker&#x000a0;&#x02014; to send electrical signals to structures responsible for body movement. Oddly, implantation sites are&#x000a0;subcortical; positive case reports in the literature of DBS' benefits in cortical myoclonus (such as posthypoxic myoclonus<xref ref-type="bibr" rid="article-25474.r68">[68]</xref> and the progressive myoclonic epilepsies) suggest that additional research into site selection and etiology-based efficacy is now warranted, even for cortical myoclonus.<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;To date, the best evidence base, including long-term follow-up,<xref ref-type="bibr" rid="article-25474.r69">[69]</xref>&#x000a0;exists for the use of DBS to treat myoclonus-dystonia syndromes,<xref ref-type="bibr" rid="article-25474.r70">[70]</xref><xref ref-type="bibr" rid="article-25474.r71">[71]</xref><xref ref-type="bibr" rid="article-25474.r72">[72]</xref> although larger-scale studies are still needed to validate and replicate the more preliminary results.<xref ref-type="bibr" rid="article-25474.r1">[1]</xref></p>
        <p>Transcranial Magnetic Stimulation (TMS), a form of neuromodulation, offers insights into neuronal plasticity in the sensorimotor cortex in particular and cortical excitability more generally, although studies in large cohorts remain aspirational.<xref ref-type="bibr" rid="article-25474.r73">[73]</xref> TMS also holds out tantalizing prospects as a nonpharmacological and noninvasive treatment approach, but further study is needed to investigate efficacy, especially over the long term.<xref ref-type="bibr" rid="article-25474.r1">[1]</xref></p>
        <p>
<bold>Precision Medicine</bold>
</p>
        <p>Though still in&#x000a0;its infancy as a therapeutic approach to myoclonus, precision therapies are targets of mounting interest for pharmacotherapy. In neuroinflammatory disorders, for example, "designer" monoclonal antibodies that target chemo- and cytokines along with&#x000a0;soluble receptor ligands and proteomic small molecule therapies represent recent advances with exciting potential for targeted therapies.<xref ref-type="bibr" rid="article-25474.r74">[74]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25474.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for myoclonus is exceptionally broad. In considering a patient presenting with myoclonus, the clinician's goal must be to distinguish myoclonus from other paroxysmal and abnormal movements. The list of such abnormal movements is long, but at a minimum, consideration should be given to tremor, tics, dystonia,&#x000a0;chorea, hemiballismus, and seizures.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Tremor: Tremor is, by definition, a rhythmic and oscillating movement. With some uncommon exceptions, myoclonus is not rhythmic, making differentiation from myoclonus relatively simple.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tics: Tics are short, abnormal, and stereotyped movements that may occur in a stereotyped sequence. Commonly observed motoric tics include grimacing, grunting, coughing, sniffing, repetitive blinking, or vocalizations. Simple tics can be challenging to distinguish from myoclonus, but the compelling urge to move experienced with tics is mainly absent from myoclonus.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dystonia: Dystonia is an abnormal movement characterized by bizarre posturing of the limbs or twisting and repetitive movements; in both cases, the dystonic movements arise from sustained muscle contractions.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chorea: Chorea is a movement disorder causing sudden, unintended, and uncontrollable smooth or jerky movements of the arms, legs, and facial muscles. As such, it can be challenging to distinguish from myoclonus. Generally, choreiform movements will be more sustained and less lightening-like than myoclonus.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hemiballismus: Hemiballistic movements are coarser, often more violent, and almost always larger in amplitude than myoclonus: the unilateral "flinging" movement of the arm or leg in hemiballismus ("ballism" means 'to throw") is much more dramatic than in myoclonic "jerks." The etiology of hemiballismus is&#x000a0;classically that of&#x000a0;a vascular insult (stroke) to the contralateral subthalamic nucleus. In recent years, however, the anatomic localization has been expanded to include that of the globus pallidus interna (part of the basal ganglia), and the pathologic diagnosis has broadened to include non-ketotic hyperglycemia and HIV infection.<xref ref-type="bibr" rid="article-25474.r75">[75]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Seizure activity: several epilepsy syndromes, both well-known and rare, include myoclonic jerks. In many instances, the myoclonus is the seizure ictus; in others, it is considered a seizure "fragment." Examples of the latter include eyelid myoclonus occurring as part of an absence seizure or myoclonus associated with focal motor seizures (eg, epilepsia partialis continua).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Functional jerks:&#x000a0;Since functional myoclonus is among the most common functional&#x000a0;movement disorders, it is crucial to&#x000a0;differentiate it from organic myoclonus. This can be done through&#x000a0;the localization of the movements. Features favoring an organic cause over a functional&#x000a0;one&#x000a0;include consistent phenomenology, insidious onset, or response to&#x000a0;benzodiazepines or antiepileptic medication.<xref ref-type="bibr" rid="article-25474.r76">[76]</xref>&#x000a0;The presence of spontaneous periods of remission,&#x000a0;pronounced reduction of the myoclonus with distraction, acute onset, and sudden resolution favors the functional diagnosis of myoclonus.<xref ref-type="bibr" rid="article-25474.r77">[77]</xref></p>
          </list-item>
        </list>
        <p>Finally, myoclonus can be a feature of myriad neurological diseases and disorders. Perhaps most&#x000a0;pathognomonically&#x000a0;associated with "startle myoclonus" in Creutzfeld-Jakob disease, myoclonus can also be a feature of neurodegenerative diseases like Alzheimer disease, dementia with Lewy bodies, Parkinson disease, frontotemporal dementia, and disorders of basal ganglia or spinocerebellar degeneration, among others. Inflammatory conditions&#x02014;infectious, post-infectious, antibody-mediated, or paraneoplastic&#x02014;often feature myoclonic jerks. Metabolic derangement, toxidromes, physical encephalopathy, focal neurological insults, trauma, and malabsorption all can, but do not invariably, cause myoclonus.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-25474.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Myoclonus can cause serious disability. Despite the availability of a diverse array of pharmacological and other interventions that are at least&#x000a0;partially effective, the treatment of myoclonus remains challenging. Treatment with medication is variably effective, and the emergence of drug-related adverse events often impedes it. Evidenced-based guidelines for pharmacologic therapy are mostly lacking, as are results from large randomized clinical trials.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-25474.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Myoclonus can be the cause of significant disability, and impairments can include problems with gait, activities of daily living, and&#x000a0;possibly the emergence of intolerable frustration, which can, in turn, prompt depressive symptoms. As noted, myoclonus is often treatment-refractory, in some cases even to polypharmaceutic approaches, and this naturally exacerbates the frustrating nature of living with myoclonus. Occupational therapy can assist with the use of assistive devices to help manage myoclonic movements with large excursions. Similarly, physical therapy can help instruct the correct and safe way to employ ambulatory assistive devices.&#x000a0;</p>
      </sec>
      <sec id="article-25474.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations with neurology (neurophysiologists, movement disorders specialists, neuroimmunologists, and neurooncologists) are almost always needed. Neurosurgery, medical oncology, infectious disease specialists, and mental health practitioners can also be helpful. Physical and occupational therapists may be beneficial; knowledgeable pharmacists are always a boon.&#x000a0;</p>
      </sec>
      <sec id="article-25474.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Critically, both&#x000a0;clinicians and patients must understand that myoclonus is neither a disease nor a diagnosis. Instead, it is an important clinical sign. An underlying cause or diagnosis must be sought through history, neurologic examination, and ancillary tests that should include relevant basic laboratory testing, EEG, and EMG at a minimum. Additional testing can be considered according to the clinical presentation; ancillary evaluations could include screens for drugs and toxins, lumbar puncture, antibody panels for autoimmune and paraneoplastic syndromes, structural imaging (usually MRI), and genetic testing.</p>
        <p>The logic underlying the diagnostic approach should be carefully and thoroughly explained to the patient. The clinician should also review the rationale underlying the eventual treatment plan with the patient, including a discussion of possible&#x000a0;adverse effects and strategies to escalate pharmacotherapy if the initial approach is insufficient. Finally, the clinician should ensure that the patient understands the vital role that other support plays in treatment success: the key here is accessing all services to improve the holistic dimensions of the care plan, including psychiatric care for co-occurring depression or anxiety, along with physical and occupational therapy, all in the service of optimizing outcomes and quality of life.&#x000a0;</p>
      </sec>
      <sec id="article-25474.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Facts to&#x000a0;keep in mind&#x000a0;regarding myoclonus include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>A single individual or disease state can manifest more than&#x000a0;just a single type of myoclonus.&#x000a0;<xref ref-type="bibr" rid="article-25474.r3">[3]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>It is crucial to develop and assiduously use an efficient and pragmatic approach to the evaluation of myoclonus, building upon classification schemes&#x000a0;for clinical presentation, suspected etiology, and results of neurophysiologic testing.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Symptomatic myoclonus is the most common clinical presentation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Drug-induced myoclonus is potentially fully treatable, with resolution of symptoms upon withdrawal of the offending agent(s).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Functional jerks can mimic myoclonus, but as with all psychogenic movement disorders, treatment differs radically from "organic" myoclonus.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25474.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In myoclonus, as with most movement disorders, a multidisciplinary care team is the mainstay of effective management for the condition, both for the patient and anyone who partners in their care. Myoclonus can be alarming to see and due to its great complexities of etiology, neurophysiology, and treatment refractoriness, it is often poorly understood by medical professionals and lay people alike,&#x000a0;</p>
        <p>Depending on the etiology, the professional care team's members might number general neurology, neurophysiologists, movement disorder specialist(s), neurosurgery (in cases of hemifacial spasm requiring microvascular decompression and in cases where DBS is considered), mental health practitioners (both for supportive therapy but also for medication management in the case of treatable psychiatric comorbidities), and allied health practitioners. Other medical professionals might also become involved depending on the etiology of the myoclonus; oncologists or neurooncologists are helpful in cases with paraneoplastic etiologies and infectious disease experts can aid in disentangling possible microbial etiologies. Increasingly, access to medical genetics and genetic counselors will be needed. Access to a pharmacist conversant with movement disorders, epilepsy, and treatment of older adults is always beneficial.&#x000a0;</p>
        <p>Physical therapy can be especially helpful for myoclonus affecting the lower extremities. Honing balance and gait skills can improve the safety of ambulation, even when walking is interrupted by myoclonic jerks.&#x000a0;</p>
        <p>Occupational therapy can help "avoid trouble." In myoclonus, "trouble" can come in the form of handling boiling water or the need to use a travel mug. Weighted utensils lessen the likelihood of food being flung off of the plate or utensil. Finally, occupational therapy can help individuals with myoclonus learn appropriate joint positioning to mitigate the excursion of the jerks.&#x000a0;</p>
      </sec>
      <sec id="article-25474.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25474&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25474">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/myoclonus/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25474">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25474/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25474">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25474.s17">
        <title>References</title>
        <ref id="article-25474.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pena</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Caviness</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Physiology-Based Treatment of Myoclonus.</article-title>
            <source>Neurotherapeutics</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>1665</fpage>
            <page-range>1665-1680</page-range>
            <pub-id pub-id-type="pmid">32910414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Veen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zutt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marras</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berkovic</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Caviness</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Shibasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Koning</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
            </person-group>
            <article-title>Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.</article-title>
            <source>Mov Disord</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>11</issue>
            <fpage>1602</fpage>
            <page-range>1602-1613</page-range>
            <pub-id pub-id-type="pmid">31584223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caviness</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Myoclonus.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>1055</fpage>
            <page-range>1055-1080</page-range>
            <pub-id pub-id-type="pmid">31356293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Truong</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Bhidayasiri</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Myoclonus and parkinsonism.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2007</year>
            <volume>84</volume>
            <fpage>549</fpage>
            <page-range>549-60</page-range>
            <pub-id pub-id-type="pmid">18808970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lange</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gonzalez-Latapi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rajalingam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
              <name>
                <surname>Ebrahimi-Fakhari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gabbert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ganos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Veen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van de Warrenburg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lohmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marras</surname>
                <given-names>C</given-names>
              </name>
              <collab>on&#x02009;behalf&#x02009;of the Task Force on Genetic Nomenclature in Movement Disorders</collab>
            </person-group>
            <article-title>Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.</article-title>
            <source>Mov Disord</source>
            <year>2022</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>905</fpage>
            <page-range>905-935</page-range>
            <pub-id pub-id-type="pmid">35481685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Timmers</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Peall</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dijk</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Zutt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Bergmans</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Foncke</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
            </person-group>
            <article-title>Natural Course of Myoclonus-Dystonia in Adulthood: Stable Motor Signs But Increased Psychiatry.</article-title>
            <source>Mov Disord</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1077</fpage>
            <page-range>1077-1078</page-range>
            <pub-id pub-id-type="pmid">32212347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orsini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Minassian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Bonuccelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peroni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Michelucci</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Striano</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.</article-title>
            <source>Seizure</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>71</volume>
            <fpage>247</fpage>
            <page-range>247-257</page-range>
            <pub-id pub-id-type="pmid">31476531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chalfin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Margolesky</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pearls &#x00026; Oy-sters: Bismuth neurotoxicity from use of topical bismuth dressing for burns.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Apr</month>
            <day>02</day>
            <volume>92</volume>
            <issue>14</issue>
            <fpage>680</fpage>
            <page-range>680-681</page-range>
            <pub-id pub-id-type="pmid">30936231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrett</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Jerk-locked averaging: technique and application.</article-title>
            <source>J Clin Neurophysiol</source>
            <year>1992</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>495</fpage>
            <page-range>495-508</page-range>
            <pub-id pub-id-type="pmid">1464676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarrigiannis</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Zis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Unwin</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Blackburn</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hoggard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Billings</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Yianni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hadjivassiliou</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tremor after long term lithium treatment; is it cortical myoclonus?</article-title>
            <source>Cerebellum Ataxias</source>
            <year>2019</year>
            <volume>6</volume>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">31143451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Amiodarone-induced muscle tremor in an elderly patient: A case report.</article-title>
            <source>World J Clin Cases</source>
            <year>2022</year>
            <month>Dec</month>
            <day>06</day>
            <volume>10</volume>
            <issue>34</issue>
            <fpage>12726</fpage>
            <page-range>12726-12733</page-range>
            <pub-id pub-id-type="pmid">36579101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chandarana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saraf</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Divya</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kishore</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Myoclonus- A Review.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2021</year>
            <season>May-Jun</season>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-338</page-range>
            <pub-id pub-id-type="pmid">34446993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baid</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Asterixis.</article-title>
            <source>J Postgrad Med</source>
            <year>2016</year>
            <season>Apr-Jun</season>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-7</page-range>
            <pub-id pub-id-type="pmid">27089111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morimatsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harada</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Severe asterixis due to hypermagnesemia in chronic renal failure: a case report.</article-title>
            <source>Neurol Sci</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>2539</fpage>
            <page-range>2539-2542</page-range>
            <pub-id pub-id-type="pmid">33404861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rodden</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Schadt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Friedreich ataxia: clinical features and new developments.</article-title>
            <source>Neurodegener Dis Manag</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>267</fpage>
            <page-range>267-283</page-range>
            <pub-id pub-id-type="pmid">35766110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teive</surname>
                <given-names>HAG</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>CHF</given-names>
              </name>
              <name>
                <surname>Munhoz</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>More than ataxia - Movement disorders in ataxia-telangiectasia.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>46</volume>
            <fpage>3</fpage>
            <page-range>3-8</page-range>
            <pub-id pub-id-type="pmid">29249681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klockgether</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mariotti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paulson</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Spinocerebellar ataxia.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2019</year>
            <month>Apr</month>
            <day>11</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <pub-id pub-id-type="pmid">30975995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olfati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shoeibi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Clinical Spectrum of Tauopathies.</article-title>
            <source>Front Neurol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>944806</fpage>
            <pub-id pub-id-type="pmid">35911892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klawans</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bergen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Levodopa-induced myoclonus.</article-title>
            <source>Arch Neurol</source>
            <year>1975</year>
            <month>May</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>330</fpage>
            <page-range>330-4</page-range>
            <pub-id pub-id-type="pmid">1079721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berardelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhattacharya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bologna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Fasano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Helmich</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hutchison</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Kamble</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hn</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Macerollo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Paparella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suppa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Udupa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical neurophysiology of Parkinson's disease and parkinsonism.</article-title>
            <source>Clin Neurophysiol Pract</source>
            <year>2022</year>
            <volume>7</volume>
            <fpage>201</fpage>
            <page-range>201-227</page-range>
            <pub-id pub-id-type="pmid">35899019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caballol</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Navarro-Otano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000c1;vila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balagu&#x000e9;-Marma&#x000f1;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Fern&#x000e1;ndez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de F&#x000e0;bregas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gelp&#x000ed;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Valls-Sol&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tolosa</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Myoclonus-Dominant Corticobasal Degeneration.</article-title>
            <source>Mov Disord Clin Pract</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>649</fpage>
            <page-range>649-652</page-range>
            <pub-id pub-id-type="pmid">30637289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grijalvo-Perez</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Corticobasal degeneration.</article-title>
            <source>Semin Neurol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-73</page-range>
            <pub-id pub-id-type="pmid">24963675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowe</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rittman</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Progressive supranuclear palsy: diagnosis and management.</article-title>
            <source>Pract Neurol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>376</fpage>
            <page-range>376-383</page-range>
            <pub-id pub-id-type="pmid">34215700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bluett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pantelyat</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Apetauerova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bega</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boxer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dhall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Duquette</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kerwin</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Leegwater-Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lepage</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ljubenkov</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McFarland</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Myrick</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Plummer</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Rodriguez-Porcel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rojas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sidiropoulos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sklerov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Tuite</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>VandeVrede</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wilhelm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wills</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>694872</fpage>
            <pub-id pub-id-type="pmid">34276544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Respondek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stamelou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Josephs</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Mollenhauer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whitwell</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Arzberger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Englund</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gelpi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Pantelyat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rajput</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Swieten</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Troakes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Bordelon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Compta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Colosimo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Dodel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kassubek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krismer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lorenzl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Nestor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Poewe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rabinovici</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Schellenberg</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Seppi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Eimeren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wenning</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Boxer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <collab>Movement Disorder Society-endorsed PSP Study Group</collab>
            </person-group>
            <article-title>Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.</article-title>
            <source>Mov Disord</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>853</fpage>
            <page-range>853-864</page-range>
            <pub-id pub-id-type="pmid">28467028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beagle</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Darwish</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ranasinghe</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>La</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Karageorgiou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vossel</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Relative Incidence of Seizures and Myoclonus in Alzheimer's Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2017</year>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>211</fpage>
            <page-range>211-223</page-range>
            <pub-id pub-id-type="pmid">28826176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mastroianni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gardella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aguglia</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rubboli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Epilepsy in neurodegenerative diseases.</article-title>
            <source>Epileptic Disord</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-273</page-range>
            <pub-id pub-id-type="pmid">35596580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holla</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kamble</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Netravathi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Spectrum and Pattern of Movement Disorders in Patients with Sporadic Creutzfeldt-Jakob Disease.</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2023</year>
            <volume>13</volume>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">37152622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Termsarasab</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pitakpatapee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Frucht</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Srivanitchapoom</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) Presenting with Pure Cerebellar Ataxia.</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>585</fpage>
            <pub-id pub-id-type="pmid">30191089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Tschaidse</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reisch</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Disorders and Movement Disorders-A Systematic Review.</article-title>
            <source>Mov Disord Clin Pract</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>360</fpage>
            <page-range>360-368</page-range>
            <pub-id pub-id-type="pmid">36949803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sabater</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Escudero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ari&#x000f1;o</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Armangue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Simabukuro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Hashimoto encephalopathy in the 21st century.</article-title>
            <source>Neurology</source>
            <year>2020</year>
            <month>Jan</month>
            <day>14</day>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>e217</fpage>
            <page-range>e217-e224</page-range>
            <pub-id pub-id-type="pmid">31882532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abboud</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Probasco</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ances</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benavides</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bradshaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christo</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Fernandez-Fournier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Gadoth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grebenciucova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jammoul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matiello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morse</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rojas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rossman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Venkatesan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vernino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>Autoimmune Encephalitis Alliance Clinicians Network</collab>
            </person-group>
            <article-title>Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>92</volume>
            <issue>7</issue>
            <fpage>757</fpage>
            <page-range>757-768</page-range>
            <pub-id pub-id-type="pmid">33649022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flanagan</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Geschwind</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lopez-Chiriboga</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Blackburn</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Turaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Binks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zitser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Dunham</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rodenbeck</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Clardy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zekeridou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toledano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Vernino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Encephalitis Misdiagnosis in Adults.</article-title>
            <source>JAMA Neurol</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-39</page-range>
            <pub-id pub-id-type="pmid">36441519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhagavati</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>664664</fpage>
            <pub-id pub-id-type="pmid">33935958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balint</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meinck</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology.</article-title>
            <source>Brain</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>141</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-36</page-range>
            <pub-id pub-id-type="pmid">29053777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bastiaansen</surname>
                <given-names>AEM</given-names>
              </name>
              <name>
                <surname>van Steenhoven</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Te Vaarwerk</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>van der Flier</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Teunissen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Graaff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nagtzaam</surname>
                <given-names>MMP</given-names>
              </name>
              <name>
                <surname>Paunovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franken</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Schreurs</surname>
                <given-names>MWJ</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Smitt</surname>
                <given-names>PAE</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Seelaar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van Swieten</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jan de Jong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pijnenburg</surname>
                <given-names>YAL</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Antibodies Associated With Autoimmune Encephalitis in Patients With Presumed Neurodegenerative Dementia.</article-title>
            <source>Neurol Neuroimmunol Neuroinflamm</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37311646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vogrig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;iz-Castrillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Desestret</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giometto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Joubert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pr&#x000fc;ss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Psimaras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vedeler</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.</article-title>
            <source>Neurol Neuroimmunol Neuroinflamm</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">34006622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vogrig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gigli</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Segatti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corazza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernardini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valent</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fabris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curcio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brigo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Iacono</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Passadore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of paraneoplastic neurological syndromes: a population-based study.</article-title>
            <source>J Neurol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>267</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-35</page-range>
            <pub-id pub-id-type="pmid">31552550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jitprapaikulsan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thakolwiboon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic neurological syndrome: an evolving story.</article-title>
            <source>Neurooncol Pract</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>362</fpage>
            <page-range>362-374</page-range>
            <pub-id pub-id-type="pmid">34277016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ikawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kishitani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamisawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hamano</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM)-like Symptoms Associated with Anti-ganglionic Acetylcholine Receptor Antibodies.</article-title>
            <source>Intern Med</source>
            <year>2021</year>
            <month>Jul</month>
            <day>15</day>
            <volume>60</volume>
            <issue>14</issue>
            <fpage>2307</fpage>
            <page-range>2307-2313</page-range>
            <pub-id pub-id-type="pmid">33583893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Adult-onset idiopathic opsoclonus-myoclonus syndrome.</article-title>
            <source>Arq Bras Oftalmol</source>
            <year>2023</year>
            <month>Mar</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">36995813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Dieterich</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Update on opsoclonus-myoclonus syndrome in adults.</article-title>
            <source>J Neurol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>266</volume>
            <issue>6</issue>
            <fpage>1541</fpage>
            <page-range>1541-1548</page-range>
            <pub-id pub-id-type="pmid">30483882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adamaszek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Langner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mehrholz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heiinrich</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Opsoclonus-Myoclonus-Ataxia Syndrome Due to Covid-19.</article-title>
            <source>Cerebellum</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>1245</fpage>
            <page-range>1245-1248</page-range>
            <pub-id pub-id-type="pmid">37814146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben Mohamed</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zouari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ketata</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nabli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Blel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ben Sassi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Myoclonus status revealing COVID 19 infection.</article-title>
            <source>Seizure</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>104</volume>
            <fpage>12</fpage>
            <page-range>12-14</page-range>
            <pub-id pub-id-type="pmid">36446232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rass</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Helbok</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pfausler</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Letter to the editor: Adult-onset opsoclonus-myoclonus syndrome due to tick-borne encephalitis virus.</article-title>
            <source>Acta Neurol Belg</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>1013</fpage>
            <page-range>1013-1015</page-range>
            <pub-id pub-id-type="pmid">37587266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Myoclonic status epilepticus after severe hyperthermia in a patient with coronavirus disease 2019.</article-title>
            <source>Acute Crit Care</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>509</fpage>
            <page-range>509-512</page-range>
            <pub-id pub-id-type="pmid">35545241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheibe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scheel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hnlein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mergenthaler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schultze-Amberger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Triebkorn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ritter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hn</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Meisel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Movement disorders after hypoxic brain injury following cardiac arrest in adults.</article-title>
            <source>Eur J Neurol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>1937</fpage>
            <page-range>1937-1947</page-range>
            <pub-id pub-id-type="pmid">32416613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Lance Adams syndrome: two cases report and literature review.</article-title>
            <source>J Int Med Res</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>3000605211059933</fpage>
            <pub-id pub-id-type="pmid">35220777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asghar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aburahma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Primera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ravikumar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Post hypoxic myoclonus: A tale of two minds.</article-title>
            <source>Epilepsy Behav Rep</source>
            <year>2023</year>
            <volume>21</volume>
            <fpage>100589</fpage>
            <pub-id pub-id-type="pmid">36747905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zutt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elting</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
            </person-group>
            <article-title>Tremor and myoclonus.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2019</year>
            <volume>161</volume>
            <fpage>149</fpage>
            <page-range>149-165</page-range>
            <pub-id pub-id-type="pmid">31307597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beudel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zutt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meppelink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elting</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Stelten</surname>
                <given-names>BML</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
            </person-group>
            <article-title>Improving neurophysiological biomarkers for functional myoclonic movements.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>51</volume>
            <fpage>3</fpage>
            <page-range>3-8</page-range>
            <pub-id pub-id-type="pmid">29653908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Constantinides</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Paraskevas</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Paraskevas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stefanis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kapaki</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Corticobasal degeneration and corticobasal syndrome: A review.</article-title>
            <source>Clin Park Relat Disord</source>
            <year>2019</year>
            <volume>1</volume>
            <fpage>66</fpage>
            <page-range>66-71</page-range>
            <pub-id pub-id-type="pmid">34316603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyons</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tr&#x000e9;pel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Dowd</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis.</article-title>
            <source>J Neurol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>270</volume>
            <issue>9</issue>
            <fpage>4451</fpage>
            <page-range>4451-4465</page-range>
            <pub-id pub-id-type="pmid">37289323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caviness</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of myoclonus.</article-title>
            <source>Adv Neurol</source>
            <year>2002</year>
            <volume>89</volume>
            <fpage>19</fpage>
            <page-range>19-22</page-range>
            <pub-id pub-id-type="pmid">11968444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zutt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elting</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>van Zijl</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>van der Hoeven</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Roosendaal</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gelauff</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Peall</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
            </person-group>
            <article-title>Electrophysiologic testing aids diagnosis and subtyping of myoclonus.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Feb</month>
            <day>20</day>
            <volume>90</volume>
            <issue>8</issue>
            <fpage>e647</fpage>
            <page-range>e647-e657</page-range>
            <pub-id pub-id-type="pmid">29352095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kozlov</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Famous 'homunculus' brain map redrawn to include complex movements.</article-title>
            <source>Nature</source>
            <year>2023</year>
            <month>Apr</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">37076715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lozsadi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Myoclonus: a pragmatic approach.</article-title>
            <source>Pract Neurol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>215</fpage>
            <page-range>215-24</page-range>
            <pub-id pub-id-type="pmid">22869763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Veen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
              <name>
                <surname>van de Warrenburg</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Myoclonus-Ataxia Syndromes: A Diagnostic Approach.</article-title>
            <source>Mov Disord Clin Pract</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-24</page-range>
            <pub-id pub-id-type="pmid">33426154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haitjema</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Occam's Razor.</article-title>
            <source>Ground Water</source>
            <year>2019</year>
            <month>May</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>349</fpage>
            <pub-id pub-id-type="pmid">30958575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atarashi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>RT-QuIC as ultrasensitive method for prion detection.</article-title>
            <source>Cell Tissue Res</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>392</volume>
            <issue>1</issue>
            <fpage>295</fpage>
            <page-range>295-300</page-range>
            <pub-id pub-id-type="pmid">35084571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gardella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes.</article-title>
            <source>Epilepsia</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>60 Suppl 3</volume>
            <fpage>S77</fpage>
            <page-range>S77-S85</page-range>
            <pub-id pub-id-type="pmid">31904124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Remi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Remi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charlesworth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whalley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hitchens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mihalyo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilcock</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Levetiracetam.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>645</fpage>
            <page-range>645-649</page-range>
            <pub-id pub-id-type="pmid">30036676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iijima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oguni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Perampanel improved intractable myoclonus in two patients with myoclonus epilepsy.</article-title>
            <source>eNeurologicalSci</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>17</volume>
            <fpage>100215</fpage>
            <pub-id pub-id-type="pmid">31799456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Assenza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nocerino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tombini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Gennaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Aniello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verrotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marrelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lanzone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Di Lazzaro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bilo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Perampanel Improves Cortical Myoclonus and Disability in Progressive Myoclonic Epilepsies: A Case Series and a Systematic Review of the Literature.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>630366</fpage>
            <pub-id pub-id-type="pmid">33841303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Neshige</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hitomi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tojima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuhashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimotake</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kasama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maruyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex.</article-title>
            <source>Clin Neurophysiol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>130</volume>
            <issue>10</issue>
            <fpage>1804</fpage>
            <page-range>1804-1812</page-range>
            <pub-id pub-id-type="pmid">31401489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bianchini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bellantoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Albergati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Magrassi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Postsurgical cortical myoclonus responsive to perampanel.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-161</page-range>
            <pub-id pub-id-type="pmid">29708211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hainque</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vidailhet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cozic</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Charbonnier-Beaupel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thobois</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tranchant</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brochard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Glibert</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Drapier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mutez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Doe De Maindreville</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lebouvier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hubsch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Degos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bonnet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grabli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Legrand</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>M&#x000e9;neret</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Azulay</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bissery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zahr</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mallet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Apartis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Roze</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>May</month>
            <day>03</day>
            <volume>86</volume>
            <issue>18</issue>
            <fpage>1729</fpage>
            <page-range>1729-35</page-range>
            <pub-id pub-id-type="pmid">27053715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Post-hypoxic myoclonus; what we know and gaps in knowledge.</article-title>
            <source>Trop Doct</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>460</fpage>
            <page-range>460-463</page-range>
            <pub-id pub-id-type="pmid">37287278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Thalamus Stimulation for Myoclonus Dystonia Syndrome: Five Cases and Long-Term Follow-up.</article-title>
            <source>World Neurosurg</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>122</volume>
            <fpage>e933</fpage>
            <page-range>e933-e939</page-range>
            <pub-id pub-id-type="pmid">30419400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krause</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kupsch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gharabaghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hn</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Long-term effects of pallidal and thalamic deep brain stimulation in myoclonus dystonia.</article-title>
            <source>Eur J Neurol</source>
            <year>2021</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>1566</fpage>
            <page-range>1566-1573</page-range>
            <pub-id pub-id-type="pmid">33452690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Besa Lehmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bulman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Verhagen Metman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A Case Report of Myoclonus-Dystonia with Isolated Myoclonus Phenotype and Novel Mutation Successfully Treated with Deep Brain Stimulation.</article-title>
            <source>Neurol Ther</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>187</fpage>
            <page-range>187-191</page-range>
            <pub-id pub-id-type="pmid">32274660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosutzka</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tisch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bonnet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hainque</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Welter</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Viallet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Karachi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jahanshahi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rivaud-Pechoux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grabli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roze</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vidailhet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term GPi-DBS improves motor features in myoclonus-dystonia and enhances social adjustment.</article-title>
            <source>Mov Disord</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-94</page-range>
            <pub-id pub-id-type="pmid">30302819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nardone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Versace</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>H&#x000f6;ller</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sebastianelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brigo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lochner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Golaszewski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saltuari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Trinka</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Transcranial magnetic stimulation in myoclonus of different aetiologies.</article-title>
            <source>Brain Res Bull</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>140</volume>
            <fpage>258</fpage>
            <page-range>258-269</page-range>
            <pub-id pub-id-type="pmid">29803873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pranzatelli</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.</article-title>
            <source>Front Immunol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>557</fpage>
            <pub-id pub-id-type="pmid">29670611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grandas</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Hemiballismus.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2011</year>
            <volume>100</volume>
            <fpage>249</fpage>
            <page-range>249-60</page-range>
            <pub-id pub-id-type="pmid">21496584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dreissen</surname>
                <given-names>YEM</given-names>
              </name>
              <name>
                <surname>Cath</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>MAJ</given-names>
              </name>
            </person-group>
            <article-title>Functional jerks, tics, and paroxysmal movement disorders.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2016</year>
            <volume>139</volume>
            <fpage>247</fpage>
            <page-range>247-258</page-range>
            <pub-id pub-id-type="pmid">27719843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25474.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caviness</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Myoclonus: current concepts and recent advances.</article-title>
            <source>Lancet Neurol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>10</issue>
            <fpage>598</fpage>
            <page-range>598-607</page-range>
            <pub-id pub-id-type="pmid">15380156</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
